Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.

BACKGROUND The goal of screening mammography is to detect small malignant tumors before they grow large enough to cause symptoms. Effective screening should therefore lead to the detection of a greater number of small tumors, followed by fewer large tumors over time. METHODS We used data from the Surveillance, Epidemiology, and End Results (SEER) program, 1975 through 2012, to calculate the tumor-size distribution and size-specific incidence of breast cancer among women 40 years of age or older. We then calculated the size-specific cancer case fatality rate for two time periods: a baseline period before the implementation of widespread screening mammography (1975 through 1979) and a period encompassing the most recent years for which 10 years of follow-up data were available (2000 through 2002). RESULTS After the advent of screening mammography, the proportion of detected breast tumors that were small (invasive tumors measuring <2 cm or in situ carcinomas) increased from 36% to 68%; the proportion of detected tumors that were large (invasive tumors measuring ≥2 cm) decreased from 64% to 32%. However, this trend was less the result of a substantial decrease in the incidence of large tumors (with 30 fewer cases of cancer observed per 100,000 women in the period after the advent of screening than in the period before screening) and more the result of a substantial increase in the detection of small tumors (with 162 more cases of cancer observed per 100,000 women). Assuming that the underlying disease burden was stable, only 30 of the 162 additional small tumors per 100,000 women that were diagnosed were expected to progress to become large, which implied that the remaining 132 cases of cancer per 100,000 women were overdiagnosed (i.e., cases of cancer were detected on screening that never would have led to clinical symptoms). The potential of screening to lower breast cancer mortality is reflected in the declining incidence of larger tumors. However, with respect to only these large tumors, the decline in the size-specific case fatality rate suggests that improved treatment was responsible for at least two thirds of the reduction in breast cancer mortality. CONCLUSIONS Although the rate of detection of large tumors fell after the introduction of screening mammography, the more favorable size distribution was primarily the result of the additional detection of small tumors. Women were more likely to have breast cancer that was overdiagnosed than to have earlier detection of a tumor that was destined to become large. The reduction in breast cancer mortality after the implementation of screening mammography was predominantly the result of improved systemic therapy.

[1]  R. Carlson Lymph Node Status Losing Importance in Breast Cancer , 2011 .

[2]  D. Kopans Arguments against mammography screening continue to be based on faulty science. , 2014, The oncologist.

[3]  H. Welch,et al.  The natural history of invasive breast cancers detected by screening mammography. , 2008, Archives of internal medicine.

[4]  B. Møller,et al.  Effect of organised mammography screening on stage-specific incidence in Norway: population study , 2016, British Journal of Cancer.

[5]  P. Gøtzsche,et al.  Effect of screening mammography on breast cancer incidence. , 2013, The New England journal of medicine.

[6]  Anne Marie Murphy,et al.  Beyond the mammography quality standards act: measuring the quality of breast cancer screening programs. , 2014, AJR. American journal of roentgenology.

[7]  X. Castells,et al.  Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program , 2015, Breast Cancer Research and Treatment.

[8]  J. Elmore,et al.  Projecting the benefits and harms of mammography using statistical models: proof or proofiness? , 2015, Journal of the National Cancer Institute.

[9]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[10]  Anthony B. Miller,et al.  Why have breast cancer mortality rates declined , 2015 .

[11]  H. Gilbert Welch,et al.  Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence , 2013 .

[12]  Mitchell H Gail,et al.  Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Merrill,et al.  How representative are the surveillance, epidemiology, and end results (SEER) Program cancer data of the United States? , 2004, Cancer Causes & Control.

[14]  R. Blanks,et al.  Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality , 2000, BMJ : British Medical Journal.

[15]  B. Hankey,et al.  Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. , 1995, Cancer.

[16]  Marvin Zelen,et al.  Effect of screening mammography on breast-cancer mortality in Norway. , 2010, The New England journal of medicine.

[17]  Klim McPherson,et al.  Observational intensity bias associated with illness adjustment: cross sectional analysis of insurance claims , 2013, BMJ : British Medical Journal.

[18]  S. Duffy,et al.  Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme 1990–96 , 2002, British Journal of Cancer.

[19]  P. Prorok,et al.  Lead time and overdiagnosis. , 2014, Journal of the National Cancer Institute.

[20]  Russell P. Harris,et al.  Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods , 2015, BMJ : British Medical Journal.

[21]  K. Rostgaard,et al.  Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period of 1978–1994? , 2010, Acta oncologica.

[22]  Per-Henrik Zahl DrMedSci,et al.  Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening , 2014, Journal of General Internal Medicine.

[23]  Laura Esserman,et al.  Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.

[24]  Rediet Abebe,et al.  Breast Cancer Screening, Incidence, and Mortality Across US Counties. , 2015, JAMA internal medicine.

[25]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[26]  C. Hudis Biology before Anatomy in Early Breast Cancer--Precisely the Point. , 2015, The New England journal of medicine.

[27]  P. Gøtzsche,et al.  Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening , 2014, Journal of general internal medicine.

[28]  D. Berry Impact of screening mammography on breast cancer mortality , 2016 .

[29]  H. Welch,et al.  Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. , 2015, The New England journal of medicine.